Login to Your Account

Colby Lands Immunotherapy Platform; $140M to MannKind

By Marie Powers
Staff Writer

Wednesday, November 14, 2012
Privately held Colby Pharmaceutical Co. continued a wave of wheeling and dealing by paying up to $140 million in up-front and milestone payments to MannKind Corp. for disease-specific antigen compounds and intra-lymph node injection (INLI) technologies from its MKC1106 cancer vaccine program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription